HHLR ADVISORS, LTD.
13F Holdings and Portfolio Analysis
Zhang Lei 2023 Q4 13F holdings, quarterly changes, portfolio value trend and position weight distribution.
HHLR ADVISORS, LTD. Overview
HHLR ADVISORS, LTD. held 49 stocks in 2023 Q4, with total market value around $4.96B.
HHLR ADVISORS, LTD.'s top five holdings in 2023 Q4: PDD HOLDINGS INC COMMON STOCK(PDD) 29.81%, BeOne Medicines AG(ONC) 18.82%, KE Holdings Inc.(BEKE) 9.55%, Legend Biotech Corporation(LEGN) 7.26%, MICROSOFT CORP COM(MSFT) 5.53%.
- Portfolio Value
- $4.96B
- Current Holdings
- 49 stocks
- New / Increased
- 1 / 4
- Reduced / Exited
- 15 / 12
Current Holdings
| 1 | PDD HOLDINGS INC COMMON STOCKPDD | 1.48 | 29.81% | 10.11 +37.55% | $146.31 | $88.14 -39.75% | $93.56 | +2.76 | 1.75 | -$0.05B-5.79% | Increased |
| 2 | BeOne Medicines AGONC | 0.93 | 18.82% | 5.18 - | $180.36 | $316.42 +75.44% | $136.90 | 0.00 | 5.25 | +$0.93B+131.14% | Held |
| 3 | KE Holdings Inc.BEKE | 0.47 | 9.55% | 29.22 -4.70% | $16.21 | $18.29 +12.83% | $18.23 | -1.44 | 3.50 | +$0.00B+0.35% | Reduced |
| 4 | Legend Biotech CorporationLEGN | 0.36 | 7.26% | 5.98 -7.02% | $60.17 | $31.96 -46.88% | $69.94 | -0.45 | 3.75 | -$0.23B-54.30% | Reduced |
| 5 | MICROSOFT CORP COMMSFT | 0.27 | 5.53% | 0.73 -9.02% | $376.04 | $460.25 +22.39% | $311.86 | -0.07 | 1.75 | +$0.11B+47.58% | Reduced |
| 6 | Salesforce, Inc.CRM | 0.20 | 3.96% | 0.75 -17.73% | $263.14 | $210.90 -19.85% | $207.81 | -0.16 | 4.00 | +$0.00B+1.48% | Reduced |
| 7 | Take-Two Interactive Software, Inc.TTWO | 0.13 | 2.54% | 0.78 - | $160.95 | $261.35 +62.38% | $147.16 | 0.00 | 0.75 | +$0.09B+77.60% | Held |
| 8 | Amazon.com, Inc.AMZN | 0.12 | 2.49% | 0.81 +1.23% | $151.94 | $264.24 +73.91% | $136.29 | +0.01 | 1.75 | +$0.10B+93.88% | Increased |
| 9 | Danaher CorporationDHR | 0.11 | 2.20% | 0.47 +450.99% | $231.34 | $178.12 -23.01% | $232.91 | +0.39 | 0.75 | -$0.03B-23.52% | Increased |
| 10 | DoorDash, Inc.DASH | 0.10 | 2.06% | 1.03 -61.27% | $98.89 | $154.61 +56.35% | $50.74 | -1.63 | 3.25 | +$0.11B+204.68% | Reduced |
| 11 | Alibaba Group Holding LimitedBABA | 0.09 | 1.91% | 1.22 -39.88% | $77.51 | $125.39 +61.77% | $102.60 | -0.81 | 1.75 | +$0.03B+22.22% | Reduced |
| 12 | RAYZEBIO INCRYZB | 0.07 | 1.33% | 1.06 -23.88% | $62.17 | - | $22.20 | -0.33 | 0.50 | +$0.04B+180.05% | Reduced |
| 13 | BAIDU INC - SPON ADRBIDU | 0.06 | 1.28% | 0.54 - | $119.09 | - | $147.19 | 0.00 | 1.00 | -$0.02B-19.09% | Held |
| 14 | Moody's CorporationMCO | 0.06 | 1.23% | 0.16 | $390.56 | $459.29 +17.60% | $390.56 | +0.16 | 0.25 | +$0.01B+17.60% | New |
| 15 | Cytek Biosciences, Inc.CTKB | 0.06 | 1.22% | 6.66 - | $9.12 | $3.95 -56.69% | $21.41 | 0.00 | 2.50 | -$0.12B-81.55% | Held |
| 16 | BridgeBio Pharma, Inc.BBIO | 0.06 | 1.13% | 1.39 -50.00% | $40.37 | $54.92 +36.04% | $40.51 | -1.39 | 4.75 | +$0.02B+35.57% | Reduced |
| 17 | ENFUSION INCENFN | 0.05 | 0.97% | 4.98 - | $9.70 | - | $20.94 | 0.00 | 2.25 | -$0.06B-53.68% | Held |
| 18 | JD.com, Inc.JD | 0.04 | 0.84% | 1.45 +184.62% | $28.89 | $33.07 +14.47% | $38.36 | +0.94 | 5.25 | -$0.01B-13.78% | Increased |
| 19 | Coupang, Inc.CPNG | 0.04 | 0.72% | 2.22 -14.06% | $16.19 | $16.68 +3.03% | $18.62 | -0.36 | 2.50 | -$0.00B-10.44% | Reduced |
| 20 | H World Group LimitedHTHT | 0.03 | 0.63% | 0.94 -61.53% | $33.44 | $37.79 +13.01% | $47.28 | -1.50 | 3.75 | -$0.01B-20.07% | Reduced |
| 21 | Neumora Therapeutics, Inc.NMRA | 0.03 | 0.58% | 1.70 - | $17.05 | $1.73 -89.85% | $14.11 | 0.00 | 0.50 | -$0.02B-87.74% | Held |
| 22 | Mondelez International, Inc.MDLZ | 0.03 | 0.54% | 0.37 -16.19% | $72.43 | $62.41 -13.83% | $40.03 | -0.07 | 5.25 | +$0.01B+55.91% | Reduced |
| 23 | Yatsen Holding LimitedYSG | 0.03 | 0.52% | 34.94 - | $0.73 | $8.42 +1050.90% | $2.24 | 0.00 | 3.25 | +$0.22B+275.54% | Held |
| 24 | ZTO Express (Cayman) Inc.ZTO | 0.02 | 0.35% | 0.81 -39.71% | $21.28 | $18.98 -10.81% | $25.70 | -0.54 | 1.00 | -$0.01B-26.14% | Reduced |
| 25 | FULL TRUCK ALLIANCE CO LTDYMM | 0.02 | 0.32% | 2.25 -36.26% | $7.01 | - | $14.04 | -1.28 | 2.00 | -$0.02B-50.08% | Reduced |
Showing 1-25 of 49
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis is an estimate and can differ materially from the actual cost, especially in edge cases.
Cost basis estimate: from the latest uninterrupted holding period, new or increased shares are added to the cost pool at the report price; reductions remove shares at the then-average cost. Example: buy 100 shares at $10 in Q1 and add 50 shares at $16 in Q2, estimated cost basis is (100 x 10 + 50 x 16) / 150 = $12 per share.
Return shows estimated dollar return on top and percentage return below. It uses current price when available, otherwise report price.
Exited Holdings
Stocks no longer disclosed in the current 13F portfolio for 2023 Q4.
| 1 | DAQO NEW ENERGY CORPDQ | 2.04 | 1.75 | $68.07 | $30.27 | -$0.08B-55.53% |
| 2 | Roivant Sciences Ltd.ROIV | 2.45 | 0.50 | $11.34 | $11.68 | +$0.00B+3.02% |
| 3 | Thermo Fisher Scientific Inc.TMO | 0.03 | 0.75 | $555.75 | $530.79 | -$0.00B-4.49% |
| 4 | Akero Therapeutics, Inc.AKRO | 0.27 | 4.50 | $99.61 | $50.58 | -$0.01B-49.22% |
| 5 | EXACT SCIENCES CORPEXAS | 0.20 | 0.75 | $71.48 | $68.22 | -$0.00B-4.55% |
| 6 | Kiniksa Pharmaceuticals International, plcKNSA | 0.70 | 5.00 | $34.80 | $17.37 | -$0.01B-50.08% |
| 7 | BioMarin Pharmaceutical Inc.BMRN | 0.11 | 0.75 | $97.24 | $88.48 | -$0.00B-9.01% |
| 8 | argenx SEARGX | 0.02 | 0.50 | $389.73 | $491.63 | +$0.00B+26.15% |
| 9 | TESLA INC COMTSLA | 0.03 | 0.25 | $250.22 | $248.48 | -$0.00B-0.70% |
| 10 | AXSOME THERAPEUTICS INCAXSM | 0.10 | 0.50 | $71.86 | $69.89 | -$0.00B-2.74% |
| 11 | AMBRX BIOPHARMA INCAMAM | 0.03 | 0.25 | $11.50 | $11.50 | $0.00B0.00% |
| 12 | Surrozen, Inc.SRZNW | 0.38 | 2.25 | $1.14 | $0.04 | -$0.00B-96.39% |
Showing 1-12 of 12
Exited holdings are stocks disclosed in the previous report period but no longer disclosed in the current 13F portfolio.
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis uses the same weighted cost-pool method as current holdings. Estimated exit price uses the current report period weighted report price when available, otherwise the previous report price; it does not represent the actual sale price.
Exit return shows estimated dollar return on top and percentage return below.
Portfolio Visuals
Track portfolio value, position weights and Top 10 history.